Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy

Anand Srivastava, Beverley Adams-Huet, Gloria L. Vega, Robert D. Toto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) can improve dyslipidemia in patients with diabetes and albuminuria. Whether combined ACEi+ARB or ACEi +mineralocorticoid receptor blockade improves dyslipidemia is not known. We hypothesized long-term administration of either losartan 100 mg or spironolactone 25 mg once daily added onto lisinopril 80 mg once daily would improve dyslipidemia in diabetic nephropathy (DN). We measured lipid levels, very-low-density (V), intermediate-density (I), low-density (LDL), highdensity (HDL) lipoprotein, LDL particle size with their respective cholesterol (C) and apolipoprotein B levels (ApoB), and urine albumin/creatinine ratio (UACR) at 12-week interval during a 48-week randomized, double-blind placebo-controlled trial in 81 patients with DN. Plasma lipids and lipoprotein C were analyzed enzymatically and Apo B was determined chemically. Data were analyzed by mixed model repeated measures. UACR differed among treatment arms ( placebo '24.6%, los '38.2%, spiro '51.6%, p=0.02). No correlation existed between UACR and TG or any of the lipid or lipoprotein measurements. Compared with placebo losartan, but not spironolactone, decreased TG ('20.9% vs +34.3%, p<0.01), V+I C('18.8% vs +21.3%, p<0.01), and V+I-ApoB ('13.2% vs +21%, p<0.01). There were no significant changes in body weight, HbA1c or other lipoprotein variables. We conclude losartan improves dyslipidemia in patients with DN. We speculate the mechanism improved clearance of VLDL and remnant lipoproteins.

Original languageEnglish (US)
Pages (from-to)1102-1108
Number of pages7
JournalJournal of Investigative Medicine
Volume64
Issue number6
DOIs
StatePublished - Aug 1 2016

Fingerprint

Spironolactone
Losartan
Diabetic Nephropathies
Dyslipidemias
Lipoproteins
Apolipoproteins B
Triglycerides
Angiotensin-Converting Enzyme Inhibitors
Albumins
Creatinine
Angiotensin Receptor Antagonists
Placebos
Urine
Lipids
Lisinopril
Mineralocorticoid Receptors
Body Weight Changes
Albuminuria
VLDL Lipoproteins
HDL Lipoproteins

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy. / Srivastava, Anand; Adams-Huet, Beverley; Vega, Gloria L.; Toto, Robert D.

In: Journal of Investigative Medicine, Vol. 64, No. 6, 01.08.2016, p. 1102-1108.

Research output: Contribution to journalArticle

@article{4f872dde88714558a61211b99caab739,
title = "Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy",
abstract = "Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) can improve dyslipidemia in patients with diabetes and albuminuria. Whether combined ACEi+ARB or ACEi +mineralocorticoid receptor blockade improves dyslipidemia is not known. We hypothesized long-term administration of either losartan 100 mg or spironolactone 25 mg once daily added onto lisinopril 80 mg once daily would improve dyslipidemia in diabetic nephropathy (DN). We measured lipid levels, very-low-density (V), intermediate-density (I), low-density (LDL), highdensity (HDL) lipoprotein, LDL particle size with their respective cholesterol (C) and apolipoprotein B levels (ApoB), and urine albumin/creatinine ratio (UACR) at 12-week interval during a 48-week randomized, double-blind placebo-controlled trial in 81 patients with DN. Plasma lipids and lipoprotein C were analyzed enzymatically and Apo B was determined chemically. Data were analyzed by mixed model repeated measures. UACR differed among treatment arms ( placebo '24.6{\%}, los '38.2{\%}, spiro '51.6{\%}, p=0.02). No correlation existed between UACR and TG or any of the lipid or lipoprotein measurements. Compared with placebo losartan, but not spironolactone, decreased TG ('20.9{\%} vs +34.3{\%}, p<0.01), V+I C('18.8{\%} vs +21.3{\%}, p<0.01), and V+I-ApoB ('13.2{\%} vs +21{\%}, p<0.01). There were no significant changes in body weight, HbA1c or other lipoprotein variables. We conclude losartan improves dyslipidemia in patients with DN. We speculate the mechanism improved clearance of VLDL and remnant lipoproteins.",
author = "Anand Srivastava and Beverley Adams-Huet and Vega, {Gloria L.} and Toto, {Robert D.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1136/jim-2016-000102",
language = "English (US)",
volume = "64",
pages = "1102--1108",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Effect of losartan and spironolactone on triglyceride-rich lipoproteins in diabetic nephropathy

AU - Srivastava, Anand

AU - Adams-Huet, Beverley

AU - Vega, Gloria L.

AU - Toto, Robert D.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) can improve dyslipidemia in patients with diabetes and albuminuria. Whether combined ACEi+ARB or ACEi +mineralocorticoid receptor blockade improves dyslipidemia is not known. We hypothesized long-term administration of either losartan 100 mg or spironolactone 25 mg once daily added onto lisinopril 80 mg once daily would improve dyslipidemia in diabetic nephropathy (DN). We measured lipid levels, very-low-density (V), intermediate-density (I), low-density (LDL), highdensity (HDL) lipoprotein, LDL particle size with their respective cholesterol (C) and apolipoprotein B levels (ApoB), and urine albumin/creatinine ratio (UACR) at 12-week interval during a 48-week randomized, double-blind placebo-controlled trial in 81 patients with DN. Plasma lipids and lipoprotein C were analyzed enzymatically and Apo B was determined chemically. Data were analyzed by mixed model repeated measures. UACR differed among treatment arms ( placebo '24.6%, los '38.2%, spiro '51.6%, p=0.02). No correlation existed between UACR and TG or any of the lipid or lipoprotein measurements. Compared with placebo losartan, but not spironolactone, decreased TG ('20.9% vs +34.3%, p<0.01), V+I C('18.8% vs +21.3%, p<0.01), and V+I-ApoB ('13.2% vs +21%, p<0.01). There were no significant changes in body weight, HbA1c or other lipoprotein variables. We conclude losartan improves dyslipidemia in patients with DN. We speculate the mechanism improved clearance of VLDL and remnant lipoproteins.

AB - Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) can improve dyslipidemia in patients with diabetes and albuminuria. Whether combined ACEi+ARB or ACEi +mineralocorticoid receptor blockade improves dyslipidemia is not known. We hypothesized long-term administration of either losartan 100 mg or spironolactone 25 mg once daily added onto lisinopril 80 mg once daily would improve dyslipidemia in diabetic nephropathy (DN). We measured lipid levels, very-low-density (V), intermediate-density (I), low-density (LDL), highdensity (HDL) lipoprotein, LDL particle size with their respective cholesterol (C) and apolipoprotein B levels (ApoB), and urine albumin/creatinine ratio (UACR) at 12-week interval during a 48-week randomized, double-blind placebo-controlled trial in 81 patients with DN. Plasma lipids and lipoprotein C were analyzed enzymatically and Apo B was determined chemically. Data were analyzed by mixed model repeated measures. UACR differed among treatment arms ( placebo '24.6%, los '38.2%, spiro '51.6%, p=0.02). No correlation existed between UACR and TG or any of the lipid or lipoprotein measurements. Compared with placebo losartan, but not spironolactone, decreased TG ('20.9% vs +34.3%, p<0.01), V+I C('18.8% vs +21.3%, p<0.01), and V+I-ApoB ('13.2% vs +21%, p<0.01). There were no significant changes in body weight, HbA1c or other lipoprotein variables. We conclude losartan improves dyslipidemia in patients with DN. We speculate the mechanism improved clearance of VLDL and remnant lipoproteins.

UR - http://www.scopus.com/inward/record.url?scp=85006165999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006165999&partnerID=8YFLogxK

U2 - 10.1136/jim-2016-000102

DO - 10.1136/jim-2016-000102

M3 - Article

C2 - 27388615

AN - SCOPUS:85006165999

VL - 64

SP - 1102

EP - 1108

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 6

ER -